Pharmaceutical Executive-03-01-2019

Pharmaceutical Executive

Perspectives from big pharma and the rare disease space on how patient advocacy is evolving as a corporate function.

Pharmaceutical Executive

Working group explores the challenges of patient support programs (PSPs) and market research programs (MRPs) for pharmacovigilance (PV) professionals-and solutions currently being put into practice.

Pharmaceutical Executive
Features

March 14, 2019

Providers of patient service solutions for pharma companies share insights on the nuances of the "consumer' connection and the shifts taking place in making patient-centric programs and tools more alive for patients.

Pharmaceutical Executive
From the Editor

March 14, 2019

That often-muddled picture is becoming increasingly clearer in the patient and business context as different ways in which patients, patient communities, advocacy, and pharma engage each other converge.

Pharmaceutical Executive
Features

March 14, 2019

Amicus Therapeutics CEO John Crowley, whose biotech journey and quest to cure two of his kids of a rare genetic disease is well chronicled, discusses the growing role of the patient-centered view in company culture-not just in adding “deeper meaning” to drug development, but in building patient advocacy into everyday business practice and strategy.

Features
Pharmaceutical Executive

March 14, 2019

Efforts to collaborate around patient engagement in every phase of product development are illustrating the growing relationship between disease advocacy groups and industry.

Pharmaceutical Executive

Despite a “temporary fix” at the ready, pharma supply repercussions loom if exit deal isn’t reached this month.

Pharmaceutical Executive

Wide-ranging probes to target marketing, pricing, and access.

Pharmaceutical Executive
In the News

March 07, 2019

Michael J. Hennessy Jr., president of MJH Associates‚ Inc., answers questions about the acquisition of UBM Life Sciences media brands and his company’s perspective on the evolving biopharma landscape.

Pharmaceutical Executive

The importance of patient advocacy in boosting research for cystic fibrosis.

Pharmaceutical Executive

While market access functions have evolved, the same can’t be said for measures used to gauge the contribution of these activities on overall business. To that end, an industry working group has developed a common framework focused on the most relevant access performance metrics (APMs).

Pharmaceutical Executive

Benchmark survey assesses the industry’s progress so far in moving from words to action in its approach to patient centricity.

Issue PDF
Pharmaceutical Executive

March 01, 2019

Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.

Special Sponsored Section
Pharmaceutical Executive

March 01, 2019

After a prolonged period of relative stagnation, the strategically influential, clinically rich French life sciences market suddenly seems to be rediscovering its mojo-thrusting the pharma and medtech sectors into the spotlight.